Literature DB >> 6702489

Screening for iron overload using transferrin saturation.

K S Olsson, K Eriksson, B Ritter, P A Heedman.   

Abstract

People with parenchymal iron overload exhibit an elevated serum iron concentration and a raised transferrin (TIBC) saturation early in the course of the disease. They can therefore be detected by simple laboratory tests before organ damage has occurred. In this study running for 2 months, 10512 samples from approximately 8750 patients and blood donors were examined in a county hospital in Central Sweden. Abnormal TIBC saturation (greater than 70%) was found in 1.7% of the samples. This abnormality was caused by physiological fluctuations in serum iron in 44%, liver disease in 22%, blood disorder in 10%, iron therapy in 10.5% and parenchymal iron overload in 11.5%. The diagnosis of iron overload was confirmed by measuring the serum ferritin concentration and by performing the desferrioxamine test, liver biopsy, quantitative phlebotomy and family studies including HLA typing. We found a prevalence of iron overload of 0.24%. This figure is almost certainly too low because some affected patients were probably lost because of TIBC desaturation induced by inflammatory conditions.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6702489     DOI: 10.1111/j.0954-6820.1984.tb04979.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  8 in total

1.  Screening for hemochromatosis?

Authors:  F A Lederle
Journal:  J Gen Intern Med       Date:  1989 Jan-Feb       Impact factor: 5.128

2.  HLA as a marker of the hemochromatosis gene in Sweden.

Authors:  B Ritter; J Säfwenberg; K S Olsson
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

3.  HFE gene mutation (C282Y) and phenotypic expression among a hospitalised population in a high prevalence area of haemochromatosis.

Authors:  S Distante; J P Berg; K Lande; E Haug; H Bell
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

4.  HLA class I and H ferritin gene polymorphisms in normal subjects and patients with haemochromatosis.

Authors:  S J Cragg; C Darke; M Worwood
Journal:  Hum Genet       Date:  1988-09       Impact factor: 4.132

5.  The significance of haemochromatosis gene mutations in the general population: implications for screening.

Authors:  M J Burt; P M George; J D Upton; J A Collett; C M Frampton; T M Chapman; T A Walmsley; B A Chapman
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

6.  Screening for hemochromatosis in Turkey.

Authors:  Hakan Bozkaya; Mehmet Bektas; Olga Metin; Ozlem Erkan; Dicle Ibrahimoglu; Klara Dalva; Filiz Akbiyik; Selim Gurel; Abdurrahman Mithat Bozdayi; Cemal Akay; Cihan Yurdaydin; Onder Aslan; Ozden Uzunalimoglu
Journal:  Dig Dis Sci       Date:  2004-03       Impact factor: 3.199

7.  Diagnostic efficacy of screening tests for hereditary hemochromatosis.

Authors:  S Borwein; C N Ghent; L S Valberg
Journal:  Can Med Assoc J       Date:  1984-10-15       Impact factor: 8.262

8.  Frequencies of the hereditary hemochromatosis allele in different populations. Comparison of previous phenotypic methods and novel genotypic methods.

Authors:  Nils Milman; Palle Pedersen; Torkil á Steig; Gitte Vedel Melsen
Journal:  Int J Hematol       Date:  2003-01       Impact factor: 2.490

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.